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I. Introduction
The "Golden Rice case" was an experiment designed to study
the effects of genetically engineered rice on children and was
conducted in a primary school in China, with researchers from
Tufts University of Boston.' In the aftermath of the study,
disputes arose as to the adequacy of the approval process for the
research, the sufficiency of the consent given by parents of study
participants, the amount of Golden Rice ingested by participants,
and the role of the Chinese researchers in the study.2 Due in large
part to these disputes, the case serves as an excellent example of
the ethical issues associated with research conducted in emerging
countries by developed countries, as well as the necessity of
protecting vulnerable study populations.'
I Guangwen Tang et al.,fl-Carotene in Golden Rice Is As Good as f-Carotene in
Oil at Providing Vitamin A to Children, 96 AM. J. CLINICAL NUTRITION 658, 658-64, n. 1
(2012) [hereinafter Tang et al.] (describing the rice, listing organizations involved in the
study, and detailing the study subjects).
2 See infra Part V (elaborating on these categories).
3 Ethical codes have described the concept of "vulnerability" as "the inability or
incapacity to make independent decisions ... and [have] characterized vulnerable
populations by their need for special protection." COUNCIL FOR INT'L ORG. OF MED.
SCIs. (CIoMs) & WORLD MED. Ass'N, INTERNATIONAL ETHICAL GUIDELINES FOR
BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS, 17-18 (2002) [hereinafter CIOMS
GUIDELINES], available at http://www.cioms.ch/publications/layout-guide2002.pdf
(providing an example of such an ethical code for the medical profession); Leslie
London, Ethical Oversight of Public Health Research: Can Rules and IRBs Make A
Difference in Developing Countries?, 92 AM. J. PUB. HEALTH 1079, 1080 (2002); see
also WORLD MED. Ass'N, WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI:
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In Part II, this paper begins by providing background
information about research in emerging countries. Then, in Part
III, it reviews the worldwide ethical principles for research with
human subjects, including the Declaration of Helsinki,' Council
for International Organizations of Medical Sciences (CIOMS)
Guidelines,' and the United Nations Educational, Scientific, and
Cultural Organization (UNESCO) Universal Declaration on
Bioethics and Human Rights.6 Part IV follows with an analysis of
the relevant laws and regulations in specific countries and regions,
including the United States and the European Union. Part V
presents the details of the Golden Rice experiment, including the
factual background and the disputes about issues of fact. Part VI
then analyzes the unique ethical issues presented by the Golden
Rice case, referencing relevant provisions of Chinese laws and
regulations. Finally, Part VII applies the lessons of the Golden
Rice experiment to make specific recommendations for research
reform.
II. Background: Research in Emerging Countries
The globalization of clinical research is a relatively recent
phenomenon. [R]eview[ing] 300 articles reporting the results of
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS 9 (2008)
[hereinafter DECLARATION OF HELSINKI], available at http://www.wma.net/en/
30publications/l0policies/b3/17c.pdf (serving as another example); NAT'L BIOETHICS
ADVISORY COMM'N, ETHICAL AND POLICY ISSUES IN RESEARCH INVOLVING HUMAN
PARTICIPANTS: VOLUME I, REPORT AND RECOMMENDATIONS OF THE NATIONAL BIOETHICS
ADVISORY COMMISSION 85 (2001), available at http://bioethics.georgetown.edu/nbac/
human/overvoll.pdf (serving as a third such example). "Vulnerable persons are those
who are relatively (or absolutely) incapable of protecting their own interests." CIOMS
GUIDELINES, supra, at 64. For example, this includes "[i]ndividuals whose willingness
to volunteer in a clinical trial may be unduly influenced by the expectation, whether
justified or not, of benefits associated with participation, or of a retaliatory response from
senior members of a hierarchy in case of a refusal to participate." European Medicines
Agency, Note for Guidance on Good Clinical Practice, 1.61, CPMP/ICH/135/95 (July
2002). "More formally, [vulnerable persons] may have insufficient power, intelligence,
education, resources, strength, or other needed attributes to protect their own interests."
CIOMS GUIDELINES, supra, at 64.
4 DECLARATION OF HELSINKI, supra note 3.
5 CIOMS GUIDELINES, supra note 3.
6 U.N. Educ., Sci., & Cultural Org., Universal Declaration on Bioethics and
Human Rights (2006) [hereinafter UNESCO Declaration], available at
http://unesdoc.unesco.org/images/00 14/001461/146180E.pdf
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clinical trials in the New England Journal of Medicine (NEJM),
the Lancet, and the Journal of the American Medical
Association (JAMA) in 1995 and 2005, [it was] found that the
number of countries serving as trial sites outside the United
States more than doubled in 10 years, whereas the proportion of
trials conducted in the United States and Western Europe
decreased.
Research in emerging countries is becoming a big business.
For instance, a 2007 study examining an "industry-sponsored
phase 3 clinical trial . . . for the 20 largest U.S.-based
pharmaceutical companies" discovered that approximately one-
third of the trials were conducted exclusively abroad, that the
majority of study sites were outside of the United States, and that
many of the sites were in developing countries, including Eastern
Europe and the Russian Federation.' This trend was also
confirmed in a report published by the European Medicines
Agency in 2010.9 It gave "an overview of... the number of
patients, investigator sites and pivotal clinical trials" that were
included in the European Medicines Agency marketing
authorization applications submitted between January 2005 and
December 2009.'0 The report found:
61% of the patients in pivotal trials submitted [marketing
authorization applications] to the [European Medicines Agency]
during the observation period ... were from third [(non-EU)]
countries, comprising 25.9% from the [Rest of the World
("ROW")] region (Africa, Middle East/Asia/Pacific,
Australia/New Zealand, Central/South America, CIS, Eastern
Europe-non EU), and 35.2% from North America.' 1
Available sources suggest factors contributing to the
7 Seth W. Glickman et al., Ethical and Scientific Implications ofthe Globalization
of Clinical Research, 360 NEw ENG. J. MED. 816, 816 (2009).
8 Id.
9 See generally European Medicines Agency, Clinical Trials Submitted in
Marketing Authorization Applications to the EMA, EMA/INS/GCP/154352/2010 (Nov.
5, 2010) [hereinafter MAA Study] (describing the study and reporting its results).
10 Id. at 3. It is important to underscore that "[o]nly those trials identified by the
applicant as pivotal at the time of the MAA are included." Id. "Supportive trials are not
included-which means Phase I, most Phase II, and some Phase III trials." Id. Finally,
"[m]any products never come to market so the clinical trials on those products do not
appear in [the study's] data." Id.
I I Id. at 26.
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globalization of clinical trials include the realization of
"substantial cost savings," the potential to "shorten the timeline for
clinical testing," in part due to larger pools of potential research
participants, and the ability to "overcome regulatory barriers" or to
"avoid [the] increasingly bureaucratic and expensive regulatory
environment in many wealthy countries." 2 Furthermore, in many
cases,
double standards are applied to trial subjects from high income
countries and from low income countries; clinical trials which
are no longer accepted by Western European ethics committees
are approved in countries like India, China, Argentina and
Russia, where ethics committees can decide differently due to a
number of reasons.' 3
Therefore, many ethical issues related to clinical research in
emerging economies need to be discussed and analyzed.
III. Worldwide Ethical Principles for Research with
Human Subjects: The Declaration of Helsinki,
CIOMS Guidelines, and the Declaration by
UNESCO
In addition to the fundamental ethical principles of
"beneficence" and "non-maleficence,"" three basic principles
govern research conducted with human subjects. The first basic
principle is "respect for autonomy," which is regarded as the
"capacity for self-determination" to choose or refuse to become
involved in the research.'" The second is the respect for equity,
such as "equitable distribution" and equitable "access" to
research.' 6 The third basic principle is the respect for dignity of
the subject, regardless of his or her health status."
One of the first sets of guidelines regarding medical research
12 Glickman et al., supra note 7, at 816-18 (discussing many of these issues).
13 Eur. Parl. Directorate-Gen. for External Policies, Clinical Trials in Developing
Countries, 11, EXPO/B/DEVE/2008/45, PE 406.974 E (Mar. 2009) [hereinafter External
Policies].
14 See infra notes 142-47 (defining "beneficence," "non-maleficence," and other
relevant bioethical terms).
15 See CIOMS GUIDELINES, supra note 3, at 17 (grouping the principles slightly
differently).
16 See id at 61-62 (mentioning these concepts).
17 See id at 17 (discussing the elements of "[r]espect for persons").
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was adopted by the General Assembly of the World Medical
Association (WMA) in June of 1964 in the Declaration of
Helsinki." This document is considered to be the "fundamental"
ethical statement for research with human subjects and it is applied
to international medical research that is conducted globally.' 9 The
Declaration is primarily addressed to physicians;2 0 however, "other
participants in medical research involving human subjects" are
invited "to adopt [the] principles" defined by the declaration.2'
The goal is "to promote and safeguard the health of patients,
including those who are involved in medical research," keeping in
mind that "the well-being of the individual research subject must
take precedence over all other interests," such as scientific and
public interests.22
Subsequently, in 1982, CIOMS established the International
Ethical Guidelines for Biomedical Research Involving Human
Subjects.23 Some of these guidelines relate expressly to vulnerable
populations and emerging countries. 24
Finally, UNESCO has promoted the same values and
recommendations as CIOMS and the WMA, by means of its
Universal Declaration on Bioethics and Human Rights.25  This
declaration highlights the local cultural, social, and economic
18 45 C.F.R. 46: Frequently Asked Questions, U.S. DEP'T HEALTH & HUM.
SERVICES, 2-3 (2011), http://www.hhs.gov/ohrp/policy/45cfr46faqmar2Oll.pdf
(tracing "[tihe history of contemporary human subjects protections" and impliedly
placing the Declaration of Helsinki second in it). "The purpose of the WMA is to serve
humanity by endeavoring to achieve the highest international standards in Medical
Education, Medical Science, Medical Art and Medical Ethics, and Health Care for all
people in the world." About the WMA, I WORLD MED. ASS'N 1,
http://www.wma.net/en/60about/index.html.pdf~print-media-type&footer-
right-[page]/[toPage] (last visited Apr. 17, 2013). The Declaration of Helsinki has been
revised eight times, with a last revision in Seoul in 2008. See DECLARATION OF
HELSINKI, supra note 3, at I (providing this information).
19 External Policies, supra note 13, at 15 (discussing and implying this
significance); CIOMS GUIDELINES, supra note 3, at 15.
20 DECLARATION OF HELSINKI, supra note 3, 2.
21 Id.
22 Id. art. 3, 6.
23 CIOMS GUIDELINES, supra note 3.
24 See generally id. (listing guidelines that pay particular attention to vulnerable
people and developing countries).
25 UNESCO Declaration, supra note 6.
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contexts, since procedures for ethics review vary from country to
country.26 Nevertheless, even if the important factors of cultural
diversity and pluralism are given due regard, those considerations
should not be invoked to infringe upon human dignity, human
rights, and fundamental freedoms, in accordance with international
human rights law.27
Taken together, these three texts protect vulnerable subjects
participating in research in emerging countries. However, with
regard to research in emerging countries, only CIOMS defines the
conditions for undertaking research in a population with limited
resources. 28 Such research must be "responsive to the health needs
and priorities of the population" and the developed product must
"be made reasonably available for the benefit of that population."29
A double ethical and scientific review of the protocol must be
performed.3 0 The first review is to be in the country of the
sponsoring organization, using the same standards as those that
would be applied for research carried out in that country.31 The
second review is to be performed by the host country's health
authorities, in addition to a national or local ethical review
committee, in order to assure that the proposed research meets the
"requisite ethical standards."3 2
Children are considered vulnerable subjects because they are
unable to protect themselves. 33  They are not capable of giving
legally valid consent, and their health status must be protected to
26 See generally id (recognizing the existence and importance of cultural, social,
and economic aspects of human rights to bioethical considerations).
27 See HENK A.M.J. TEN HAVE & MICHELE S. JEAN, THE UNESCO UNIVERSAL
DECLARATION ON BIOETHICS AND HUMAN RIGHTS: BACKGROUND, PRINCIPLES AND
APPLICATION 96 (2009) ("[I]nternational human rights law is based on the assumption
that some basic rights transcend cultural diversity.").
28 CIOMS GUIDELINES, supra note 3, at 51.
29 Id.
30 See id. at 30 (explaining the ethical review process for research carried out in
one country but sponsored by an organization in another).
31 See id ("[T]he ethical standards applied should be no less stringent than they
would be for research carried out in that country.").
32 Id.
33 See id. at 64 ("Classes of individuals conventionally considered vulnerable are
those with limited capacity or freedom to consent or to decline to consent .. . and include
children.").
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assure that there will be no harm.3 4 The Declaration of Helsinki
does not address children as such, but they are considered persons
who are unable to consent." For CIOMS, an important issue is
whether the proposed research on children "might not equally well
be carried out with adults," because "the purpose of the research is
to obtain knowledge relevant to the health needs of children."36
Aside from permission given by a parent or legal representative of
the child, the assent of the child should be obtained in accordance
with the child's capabilities.3 7 The refusal of the child will be
respected."
However, CIOMS and Article 9 of the Declaration of Helsinki
provide conditions for vulnerable subjects who need special
protection, particularly those who cannot give or refuse consent
for themselves and those who may be vulnerable to coercion or
undue influence. Special justification is required for inviting
vulnerable individuals to serve as research subjects, and, if they
are selected, the means for protecting their rights and welfare must
be strictly applied.3 9 Research would only be justified if it is
"responsive to the health needs and priorities of this [vulnerable]
population and if there is a reasonable likelihood that this
population .. . stands to benefit from the results of the research."40
These conditions would meet CIOMS Guideline 10 for a
34 See DECLARATION OF HELSINKI, supra note 3, art. 9 (stating that particularly
vulnerable populations in need of special protection include "those who cannot give or
refuse consent for themselves and those who may be vulnerable to coercion or undue
influence"); see also CIOMS GUIDELINES, supra note 3, at 64-65 (listing the factors of
ethical justification that are required to satisfy ethical review committees in research
dealing with vulnerable groups).
35 See DECLARATION OF HELSINKI, supra note 3, art. 9 (considering those who
cannot give consent as "particularly vulnerable"); see also CIOMS GUIDELINES, supra
note 3, at 64 (naming children as a class of individuals who are generally considered
unable to give consent).
36 CIOMS GUIDELINES, supra note 3, at 66.
37 See id. (stating that an investigator must ensure that "a parent or legal
representative of each child has given permission" and that each child's agreement has
been "obtained to the extent of the child's capabilities").
38 See id. ("[A] child's refusal to participate or continue in the research will be
respected.").
39 See id. at 64-65 (listing the factors of ethical justification that are required to
satisfy ethical review committees in research dealing with vulnerable groups).
40 DECLARATION OF HELSINKI, supra note 3, art. 17.
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population with limited resources.4 1
When subjects are not capable of giving consent, research may
be conducted only when accompanied by the benefits previously
mentioned.42 If no benefit is expected, the risk from the research
should not be "greater than the risk attached to routine medical or
psychological examination of such persons."4 3
The conditions for consent are the same in the Declaration of
Helsinki and the CIOMS Guidelines. When the subject is
incompetent, informed consent can only be given by a legally
authorized representative.4 4 In addition, the physician must seek
the assent of the incompetent patient, and the refusal of the subject
must be respected.4 5
When the research "is intended to promote the health of the
population represented by the potential subject, [and] cannot
instead be performed with competent persons[,] . . . the research
[should] entail[] only minimal risk and minimal burden."46
"Waiver of informed consent is to be regarded as uncommon and
exceptional, and must in all cases be approved by an ethical
review committee." 47
41 CIOMS GUIDELINES, supra note 3, at 51.
42 See DECLARATION OF HELSINKI, supra note 3, art. 27 ("These [incompetent]
individuals must not be included in a research study that has no likelihood of benefit for
them unless it is intended to promote the health of the population represented by the
potential subject.").
43 CIOMS GUIDELINES, supra note 3, at 49.
44 See DECLARATION OF HELSINKI, supra note 3, art. 27 ("For a potential research
subject, the physician must seek informed consent from the legally authorized
representative."); see also CIOMS GUIDELINES, supra note 3, at 32 ("For all biomedical
research involving humans the investigator must obtain . . . in the case of an individual
who is not capable of giving consent, the permission of a legally authorized
representative in accordance with applicable law.").
45 See DECLARATION OF HELSINKI, supra note 3, art. 28 ("When a potential
research subject who is deemed incompetent is able to give assent to decisions about
participation in research, the physician must seek that assent in addition to the consent of
the legally authorized representative. The potential subject's dissent should be
respected.").
46 Id. art. 27.
47 CIOMS GUIDELINES, supra note 3, at 32.
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IV. Laws and Guidelines of Specific Countries and
Regions
In addition to the worldwide guidelines and recommendations
discussed above, specific countries and regions have adopted laws,
regulations, or guidelines for the performance of research with
human subjects. This section of the paper discusses the U.S. laws
and regulations and explains the bases for applying U.S. laws and
procedures to research conducted in other countries. Then, this
section discusses European guidelines and regulations, including
the Oviedo Convention,48 European Union (EU) directives, and the
"[a]ction plan" of the European Medicines Agency.4 9 Relevant
provisions of Chinese laws and regulations are discussed below in
Part VI of this paper, with specific recommendations for reform.
A. U.S. Laws and Procedures on Informed Consent for
Research Conducted in Other Countries
What are the bases for applying U.S. laws and procedures for
ethical review to research conducted elsewhere? In other words,
why do U.S. laws and review procedures apply to research
activities performed outside of the United States on human
subjects who are not residents of the United States? At least three
bases exist for the application of U.S. laws and procedures in these
circumstances: funding by U.S. government agencies, involvement
of U.S. investigators in the research, and meeting the requirements
for sale of products in the lucrative U.S. market.
The first basis is that U.S. law applies to research that is
funded by agencies of the U.S. government, as in the case of the
research on Golden Rice in China. According to the published
article in the American Journal of Clinical Nutrition, "[t]his
material is based on work supported by the U.S. Department of
Agriculture ... [and] by a grant from the National Institute of
Diabetes and Digestive and Kidney Diseases, NIH."so Federal
48 Convention for the Protection of Human Rights and Dignity of the Human
Being with Regard to the Application of Biology and Medicine, Apr. 4, 1997, E.T.S. No.
164 [hereinafter "Oviedo Convention"].
49 European Medicines Agency, Reflection Paper on Ethical and GCP Aspects of
Clinical Trials of Medicinal Products for Human Use Conducted Outside of the EU/EEA
and Submitted in Marketing Authorisation Applications to the EU Regulatory
Authorities, 10-12, EMA/121340/2011 (Apr. 16, 2012).
50 Tang et al., supra note 1, at 658 n.3.
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regulations set forth the policy of the U.S. Department of Health
and Human Services (HHS) to protect human subjects of research,
including requirements for informed consent." This is called the
"Common Rule" because it has been adopted by many other
federal agencies, including the U.S. Department of Agriculture
(USDA). 52 These rules even apply to U.S.-funded research that is
performed outside of the United States; the federal policy to
protect human subjects "also includes research . .. supported ...
by the federal government outside the United States."5 3 These
federal rules include requirements for approval of proposed
research by an Institutional Review Board, as well as specific
requirements for informed consent.54 Thus, it really does not
matter for this purpose whether the research in this case involved
genetically-modified food, non-modified food, or no food at all.
The second basis for applying U.S. principles and procedures
is the involvement of U.S. investigators in the proposed research.
Many U.S. universities have agreed to apply the same
requirements and procedures even if the study is not supported by
an agency of the federal government." This includes Tufts
University, where some of the Golden Rice researchers were
based.5 6 The Policies and Operations Manual for the Institutional
Review Board of Tufts Medical Center and Tufts University Health
51 See 45 C.F.R. § 46.116 (2012) (providing "[g]eneral requirements for informed
consent").
52 See 7 C.F.R. §§ Ic.101-124 (2012) (including the USDA section on the
protection of human subjects); see also Federal Policy for the Protection of Human
Subjects ('Common Rule'), U.S. DEP'T HEALTH & HUM. SERVICES.,
http://www.hhs.gov/ohrp/humansubjects/commonrule/index.html (last visited Apr. 17,
2013) (referring to the name "Common Rule").
53 7 C.F.R. § Ic.101(a) (2012); see also 45 C.F.R. § 46.101(a) (2012) (containing
the same language as the previous rule).
54 See 7 C.F.R. § Ic.109 (2012) ("An [Institutional Review Board] shall review
and have authority to approve, require modifications in (to secure approval), or
disapprove all research activities covered by this policy.").
55 See Robert Charrow, Protection of Human Subjects: Is Expansive Regulation
Counter-Productive?, 101 Nw. U. L. REv. 707, 716-18 (2007) (discussing "[w]hether
[these] voluntary agreement[s are] enforceable").
56 See generally Tang et al., supra note 1, at 658 n.l (listing Tufts University as
one of the organizations involved in the study); see also Jane Qiu, China Sacks Officials
over Golden Rice Controversy, NATURE (Dec. 10, 2012), http://www.nature.com/news/
china-sacks-officials-over-golden-rice-controversy-1.11998 ("The US study team was
led by Guangwen Tang, a nutrition scientist at Tufts University . . . .").
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Sciences provides that:
Federal support is not necessary for the FDA regulations to be
applicable. The vast majority of institutions/entities, including
Tufts Medical Center and TUHS . . . apply HHS regulatory
requirements to all research conducted under their auspices.
Thus, typically, industry-sponsored, privately funded research,
etc., are subject to the same requirements as federally funded
research.57
Finally, in order to obtain approval of a drug to be sold in the
lucrative U.S. market, the U.S. Food and Drug Administration
(FDA) imposes specific requirements on the sponsor of the
clinical trial." Those requirements apply even if the clinical trial
is performed in a different country.59
B. European Guidelines and Regulations
All EU member states respect the Declaration of Helsinki and
the CIOMS Guidelines.60 In 1997, the Council of Europe adopted
the "Oviedo Convention," or the Convention for the Protection of
Human Rights and Dignity of the Human Being with Regard to the
Application of Biology and Medicine.6 1 Chapter V is dedicated to
"[s]cientific research." 62  Article 15 provides that "[s]cientific
57 TUFTS MED. CTR., POLICIES AND OPERATIONS MANUAL FOR THE INSTITUTIONAL
REVIEW BOARD OF TUFTS MEDICAL CENTER AND TUFTS UNIVERSITY HEALTH SCIENCES 11
n.5 (2012).
58 See 21 C.F.R. § 312.120 (2012) (setting forth the guidelines for "[f]oreign
clinical studies" that are not performed under the FDA's investigational new drug
("IND") procedure).
59 See id (detailing the requirements when there are "[fjoreign clinical studies not
conducted under an IND"); 21 C.F.R.§ 314.106 (2012) (detailing the requirements when
there is "[fjoreign data").
60 See Jennifer J. Couture, The Changes in Informed Consent in Experimental
Procedures: The Evolution ofA Concept, I J. HEALTH & BIOMEDICAL L. 125, 148 (2004)
("The European Union, under the European Commission, follows the most current
version of the Declaration of Helsinki in regards to all analytical, pharmacological and
clinical standards for testing any experimental treatments."); see, e.g., Investigational
New Drug Safety Reporting Requirements for Human Drug and Biological Products and
Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in
Humans, 75 Fed. Reg. 59935, 59936 (proposed Sept. 29, 2010) to be codified at 21
C.F.R. §§ 312, 320 (mentioning proposed requirements that would "harmonize the
regulations" with both the CIOMS and the European Union).
61 See Oviedo Convention, supra note 48, at 7, 18 (providing the date of signing).
62 Id. arts. 15-18.
990 Vol. XXXVIII
ETHICS IN RESEARCH: GOLDENRICE
research ... shall be carried out freely, subject to the provisions of
[the] Convention and the other legal provisions ensuring the
protection of the human being."6 3 Regarding the protection of
persons who are "not able to consent," Articles 16 and 17 provide
that various "conditions" should be respected, including: "the
results of the research [must] have the potential to produce real
and direct benefit to [the person's] health" or the research should
be performed "[e]xceptionally and under the protective conditions
prescribed by law" for the "benefit [of] other persons in the same
age category or afflicted with the same disease or disorder or
having the same condition," where "the research entails only
minimal risk and minimal burden"; "authorization" must "be[]
given specifically and in writing," "the person concerned [must]
not object," and it must be the case that "research of comparable
effectiveness cannot be carried out on individuals capable of
giving consent."64
In the Additional Protocol to the Convention on Biomedical
Research of 2005, Article 15, relating to research on "persons
[who are] not able to consent," establishes that, having obtained
the "authorization [of his or her] legal representative," "[t]he
opinion of [a] minor shall be taken into consideration as an
increasingly determining factor in proportion to [the minor's] age
and degree of maturity.,65 The need to respect the will of the child
and to obtain his or her assent, taking into account his or her
degree of maturity, is one of the fundamental principles integrated
in the European Ethical Considerations for Research in
Paediatrics, which was approved by the European Commission in
2008.6 This key document aims at providing ethical guidelines
for pediatric research in both EU- and "non EU-countries."6 7
63 Id. art. 15.
64 Id. arts. 16-17.
65 Additional Protocol to the Convention on Human Rights and Biomedicine,
concerning Biomedical Research art. 15, Jan. 25, 2005, C.E.T.S. No. 195.
66 See Ethical Considerations for Clinical Trials on Medicinal Products
Conducted with the Pediatric Population: Recommendations of the Ad Hoc Group for
the Development of Implementing Guidelines for Directive 2001/20/EC Relating to Good
Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human
Use, at I1, 12 (2008), available at http://ec.europa.eu/health/files/eudralex/vol-
10/ethical considerationsen.pdf (reflecting these principles).
67 See id. at 4, 5 (discussing these goals).
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Directive 2001/20/EC did not provide for standards to be
adopted for clinical trials outside of the EU. 68  Nevertheless, in
recent years, one of the main objectives of the European Union has
been to avoid unethical clinical trials and the exploitation of
developing and emerging countries. 69  The latest version of
Directive 2001/83/EC requires that, in connection with an
application for "marketing authorization," "a statement [must be
submitted] to the effect that clinical trials carried out outside the
European Union meet the ethical requirements of Directive
2001/20/EC."70
Moreover, Article 6 of Regulation (EC) N. 726/2004, which is
related to the "centralized procedure" for Marketing Authorization
(MA), states that "[e]ach application for the authorization of a
medicinal product for human use .. . must include a statement to
the effect that clinical trials carried out outside the European
Union meet the ethical requirements of Directive 2001/20/EC."1
Recital 16 specifies that
with respect to clinical trials conducted outside the Community
on medicinal products destined to be authorized within the
68 Directive 2001/20/EC, of the European Parliament and of the Council of 4 April
2001 on the Approximation of the Laws, Regulations and Administrative Provisions of
the Member States Relating to the Implementation of Good Clinical Practice in the
Conduct of Clinical Trials on Medicinal Products for Human Use, 2001 O.J. (L 121) 34,
34-44 (containing no such specific standards, although making some allusions to "third
countries" and "multi-centre clinical trials").
69 See, e.g., Dan Phair, Orphan Drug Programs, Public-Private Partnerships and
Current Efforts to Develop Treatments for Diseases of Poverty, 4 J. HEALTH &
BIOMEDICAL L. 193, 219 (2008) ("As a condition for receiving funding, the partnership
must support clinical trials in Sub-Saharan Africa and foster capacity development
in developing countries. In particular, the Netherlands, as part of its EDCTP
commitment, has collaborated with the WHO to 'develop a regulatory framework to
ensure appropriate oversight of clinical trials in Africa.' The ultimate goal is to create
permanent regulatory infrastructure that meets international standards.").
70 Directive 2001/83/EC, of the European Parliament and of the Council of 7
November 2001 on the Community Code Relating to Medicinal Products for Human
Use, 2001 O.J. (L 311) 67, art. 8(3)(ib), available at http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:200 I L0083:20070126:EN:PD
F.
71 Regulation (EC) No. 726/2004 of the European Parliament and of the Council of
31 March 2004 Laying Down Community Procedures for the Authorization and
Supervision of Medicinal Products for Human and Veterinary Use and Establishing a
Europeans Medicines Agency, 2004 O.J. (L 136) 1, art. 6.
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Community, at the time of the evaluation of the application for
authorization, it should be verified that these trials were
conducted in accordance with the principles of good clinic
practice and the ethical requirements equivalent to the
provisions of the Directive 2001/20/EC 2
In 2012, after a public consultation, the European Medicines
Agency released a "[r]eflection paper on ethical and [good clinical
practice] aspects of clinical trials of medicinal products for human
use conducted outside of the EU/EEA and submitted in marketing
authorization applications to the EU Regulatory Authorities.""
This document establishes a number of aspects and items to be
reviewed by the EU regulatory authority in order to verify that a
study complies with internationally accepted ethical standards.7 4
In particular, the reflection provides that failure to submit a
protocol to an independent ethics committee, to obtain informed
consent (and/or assent where applicable), to provide fair
compensation by insurance or indemnity, to get approval from the
ethics committee, or to implement the appropriate consent
procedure when including vulnerable subjects in a clinical trial are
to be considered "a serious violation of ethical standards." It
also proposes that sponsors describe in detail the justification for
the use of a placebo and/or choice of active comparator in the
protocol and in the study report, in accordance with the ethical
principles referred to in the document. 76 The document points out
that, regardless of the location of the trial, all patients participating
in these trials should receive the same or similar standard of care
and comparable treatment options as trial participants within the
72 Id. at 3.
73 Eur. Medicines Agency Working Group on Clinical Trials Conducted Outside
the EU/EEA [EMA], Reflection Paper on Ethical and GCP Aspects ofClinical Trials of
Medicinal Products for Human Use Conducted Outside of the EU/EEA and Submitted in
Marketing Authorization Applications to the EU Regulatory Authorities,
EMA/121340/2011 (Apr. 16, 2012) [hereinafter Reflection Paper].
74 See id at 4 ("The scope of this Reflection Paper is to clarify the practical
application of requirements for clinical trials conducted outside of the EU/EEA and
submitted in Marketing Authorization Applications to the EMA .. . or to National
competent Authorities.").
75 Id. at 18 (emphasis added).
76 See id. at 26-28 (describing the proper use of placebo/active comparator in
research studies).
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European Economic Area.n Sponsors should also describe in
detail how the medicinal product has been or will be made
available in the countries where the trials were conducted, taking
into account that they should ensure the availability of healthcare
services essential to the safe conduct of the research, as well as of
the treatment for subjects in case of injury as a consequence of
research participation."
The Reflection Paper also proposes that a system be developed
for reviewing marketing authorization application dossiers and for
identifying potential ethical or "good clinical practice" concerns,
as well as for establishing a pool of experts at the European
Medicines Agency to advise its committees in the assessment of
the ethical aspects of clinical trials submitted in marketing
authorization applications.' Furthermore, it is proposed that
competent EU authorities should refuse to consider data that was
obtained in a manner not in accordance with the ethical standards
mentioned in the document in support of marketing authorization
applications.o Where non-compliance with applicable legislation,
guidance, and rules is identified, suspension/urgent safety
restriction/revocation of the Marketing Authorization should be
considered."' Finally, it is proposed that all of the actions adopted
by the European Medicines Agency staff, "including
approval/refusal or revocation of Marketing Authorisation for
ethical reasons," should be provided for in the European Public
Assessment Report.82
77 See id. at 4 ("The final scope of the document is to strengthen the process
(mainly in its earlier phases) to assure, at the time of MAA assessment, that clinical trials
conducted in countries outside EU/EEA have been conducted in accordance with the
principle of Good Clinical Practice (GCP) and equivalent ethical standards as those
applied/requested in the EU.").
78 See Reflection Paper, supra note 73, at 23, 29 (emphasizing the importance of
making compensation available to any subjects injured in the course of treatment and
reinforcing the requirement that applicants disclose whether and how continued
treatment may be available to subjects after the clinical trial).
79 See id. at 36 (describing the regulatory action/action plan for doing so).
80 See id at 18 (instructing EU authorities to "disregard data obtained in a such
unethical manner").
81 See id at 39 (stating that these consequences should be considered where non-
compliance is identified after the Marketing Authorization has been granted).
82 Annagrazia Altavilla, Ethical Standards for Clinical Trials Conducted in Third
Countries: The New Strategy of the European Medicine Agency, 18 EUR. J. OF HEALTH
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In July 2012, a proposal for a regulation on clinical trials83 was
published by the European Commission with the aim of repealing
Directive 2001/20/EC.84 It proposes that any clinical trial in a
developing country that is referenced in a marketing authorization
application must be conducted on the basis of principles that are
equivalent to those that are applied in the European Union.15 The
effective application of this "equivalence rule" would be
strengthened by introducing inspections of developing country
regulatory systems.86 Those inspections would verify whether the
developing country regulatory system, as well as its control and
enforcement, is equivalent to that in the European Union, in regard
to the rights of subjects, safety, and robustness of data." The main
objective is to avoid possible abuse."
V. The Golden Rice Experiment: Factual Background
and Factual Disputes
A. The Factual Background
The experiment with Golden Rice was presented as a study of
the preventive treatment of vitamin A deficiency in children89 and
LAW, at 65, 75 (2001).
83 Proposal for a Regulation of The European Parliament and of the Council on
Clinical Trials on Medicinal Products for Human Use, and Repealing Directive
2001/20/EC, COM (2012) 369 final (July 17, 2012) available at http://ec.europa
.eu/health/files/clinicaltrials/2012_07/proposal/2012_07 proposal en.pdf.
84 See id. at 10 ("The proposed Regulation addresses the aspects regulated in
Directive 2001/20/EC. That Directive is therefore repealed.").'
85 See id. art. 25(5) ("Where the clinical trial has been conducted outside the
Union, it shall comply with principles equivalent to those of this Regulation as regards
subject rights and safety and reliability and robustness of data generated in the clinical
trial.").
86 As more clinical trials are conducted outside of the EU, cooperation with
countries where these studies are conducted is essential in ensuring a "common
international approach to the oversight of clinical trials." Reflection Paper, supra note
73, at 6. Because ethics and regulatory systems in third countries are not fully
developed, it is imperative that the EU build relationships with the existing ethics
committees in these countries to ensure compliance. See id.
87 See id. at 36-37 (emphasizing the importance of inspections for monitoring
compliance with ethical and other regulatory principles).
88 See id. at 37 ("[These] measures would ensure that significant non-compliance
would not occur.").
89 See Tang et al., supra note 1, at 658 (providing that the experiment "compared
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was ultimately registered in the United States as phase II of a
study of vitamin A equivalence of plant carotenoids in children in
2008, with Tufts University as its sponsor.9 o Initial authorization
for the project came from the U.S. National Institutes of Health in
December of 2002.91 In 2003, the ethics committee of the
Zhejiang Academy of Medical Sciences reviewed and approved
the project.92 By 2004, both Tufts University and the Zhejiang
Academy of Medical Sciences had agreed to the study.93
Finally, in 2008, the research protocol was sent from Zhejiang
Province to Hunan Province.94 Thereafter, the Chinese Centers for
Disease Control and Prevention and the National Academy of
Medical Sciences of Zhejiang Province signed an agreement with
authorities in Hunan Province regarding the study.95 However, use
of Golden Rice was not clearly mentioned, nor did the head of
science and technology at the Zhejiang Academy of Medical
Sciences seek ethical approval for the trial in Hunan.96 It is
the vitamin A value of b-carotene in [Golden Rice] and in spinach with that of pure b-
carotene in oil when consumed by children").
90 See Vitamin A Equivalence of Plant Cartenoids in Children,
CLINICALTRIALS.GOV (Feb. 17, 2009), http://www.clinicaltrials.gov/ct2/show/
NCT00680212?term=NCT00680212&rank=I [hereinafter Vitamin A Equivalence]
(noting that the official title of the study is "Phase 2 Study of VITAMIN A
EQUIVALENCE OF PLANT CARTENOIDS IN CHILDREN").
91 See China Sacks Officials Involved in GM Rice Test, XINHUA (Dec. 6, 2012),
http://www.china.org.cn/china/Off the Wire/2012-12/06/content_27337035.htm
(describing the Golden Rice research project).
92 See Wang Qingyun, Better Supervision of Research Urged, CHINA DAILY-HONG
KONG EDITION, Dec. 13, 2012. (specifying that the Ethics Committee approved the
project).
93 See Wang Qingyun and Shan Juan, CDC to Probe Whether GM Study Used
Schoolchildren, CHINA DAILY-HONG KONG EDITION, Sept. 12, 2012 ("Zhejiang Academy
of Medical Sciences, said it cooperated with Tufts University in 2004."). Guangwen
Tang was responsible for the whole project, whereas Wang Yin and Shian Yin were
responsible for the study in China. See Jane Qui, China Sacks Officials over Golden
Rice Controversy, NATURE (Dec. 10, 2012), http://www.nature.com/news/china-sacks-
officials-over-golden-rice-controversy-I. 11998 (identifying Wang Yin as the head of
science and technology at Zhejiang Academy of Medical Sciences and Yin Shi'an as the
principal investigator of the Chinese Center for Disease Control and Prevention).
94 See Qui, supra note 93 (noting that the study was approved at Zhejiang
Academy of Medical Sciences and conducted in Hunan Province).
95 See id.
96 See id (providing that Chinese Centers for Disease Control and Prevention staff
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alleged, however, that the Chinese version of the informed consent
document was assessed and approved by the Ethics Committee of
Tufts University.97
After these hoops were surpassed, the experiment was
implemented in a primary school in Hunan Province.98 Sixty-eight
children were selected for participation.99 Parents of participants
met with researchers about the study, but they were not informed
as to the use of the Golden Rice.' Instead, "the informed-consent
form said that the rice contained P carotene, but not that it was
genetically modified or that it was Golden Rice." 0 ' While it was
initially reported by at least one news source that during the study,
"each group of two dozen or so children aged six to eight ate
meals containing Golden Rice, spinach, or P carotene capsules for
lunch every weekday during the three week trial,"02 the Chinese
Centers for Disease Control and Prevention's later investigation
into the study nevertheless "revealed that . .. children ate Golden
Rice just once."'O3
In September 2012, the researchers published the results of the
study in an article in the American Journal of Clinical Nutrition.10 4
Using the Chinese system of family names first, the Chinese
authors were TANG Guangwen, researcher from Tufts University;
HU Yuming, Center for Disease Control and Prevention Hunan,
China; YIN Shian, National Institute of Nutrition and Food Safety
China, led by the National Center for Disease Control and
Prevention; and WANG Yin, Zhejiang Academy of Medical
exchanged emails in which they intentionally avoided mentioning "Golden Rice" in
documents).
97 Tang et al., supra note 1, at 659.
98 Id
99 Id at 658.
100 See Qui, supra note 93 (noting that neither the informed consent forms nor the
researchers conducting the study mentioned the use of golden rice).
101 Id.
102 Id
03 Id. Tang cooked the rice in the United States and transported it to China in May
2008, without declaring it with Chinese customs. Tian Ying et al., China Sacks Officials
Involved with GM Rice Test, XINHUA (Dec. 6, 2012), http://news.xinhuanet.com/
english/china/2012-12/06/c_132024160.htm.
104 Tang et al., supra note 1, at 658-64.
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Sciences.105
Shortly after publication, Greenpeace China criticized the
authors for performing experiments on the effect of transgenic rice
on children aged six to eight years old.' 0 6 As a result, Chinese
agricultural officials asked the Academy of Medical Sciences of
Zhejiang Province to investigate these events.'07 Some Chinese
collaborators distanced themselves from the work.' Hu and
Wang stated that they did not know why their names appeared on
the paper.'09 The Chinese Centers for Disease Control and
Prevention suspended one of these authors for "inconsistencies" in
his story."o Ultimately, the authorities of Hunan Province offered
financial compensation to the participants in the amount of
Y80,000 for the twenty-five children who received the Golden
Rice and Y10,000 per person for the others."'
B. Disputes About Issues ofFact
In the Golden Rice case, at least four categories of factual
disputes arose. These included facts about the process for
approval of the research, facts about informed consent by the
parents, facts about the amount of Golden Rice eaten by the
children, and facts about the role of the Chinese researchers.
First, facts about the process for approval of this research were
in dispute. According to the published article, "[t]he study
recruitment processes and protocol were approved by the
105 Id. at 658.
106 Press Release, Greenpeace International, Greenpeace Alarmed at US-Backed
GE Food Trial on Chinese Children (Aug. 29, 2012), available at
http://www.gmwatch.org/latest-listing/51-2012/14157.
107 See Mara Hvistendhal & Martin Enserink, Charges Fly, Confusion Reigns Over
Golden Rice Study in Chinese Children, 1337 SCI. 1281, 1281 (2012) (explaining the
sequence of events leading from the Greenpeace press release to the Zhejiang Academy
of Medical Sciences' decision to stop the Tang study).
108 See id. (providing quotes found in Chinese state-run media from purported co-
authors Chinese Hu Yuming and Wang Yin claiming to be "completely baffled" and
"unaware" of the Tang article).
109 Id.
110 Id.
11I Qiu Quanlin, Parents of Students in GM Rice Test Win Payout, CHINA DAILY
(Dec. 8, 2012), http://www.chinadaily.com.cn/china/2012-12/08/content_15996929.htm
[hereinafter Quanlin] (stating that the families of the 25 children received what was the
equivalent of $12,800).
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Institutional Review Board-Tufts Medical Center in the United
States and by the Ethics Review Committee of Zhejiang Academy
of Medical Sciences in China.""l2  However, China's Center for
Disease Control and Prevention stated that one of the researchers
(Wang) had faked the documents for approval."'
Second, facts about informed consent by the parents were in
dispute. According to the article, "[b]oth parents and pupils
consented to participate in the study."I' However, reports
indicated that parents did not know their children were eating
genetically-modified rice, and were not informed about any
potential risks of genetically-modified food."'
Third, facts were in dispute about the amount of Golden Rice
which was eaten by the children who participated in the study.
The published article described a study period which lasted three
weeks."'6  However, as noted in one media report, "the [Chinese
Centers for Disease Control and Prevention's] investigation
revealed that the children ate Golden Rice just once during the
study."'"
Finally, facts about the role of Chinese researchers were in
dispute. According to the published article, Yuming Hu
supervised and coordinated the study, Shi-an Yin collected
samples and conducted the study, and Yin Wang supervised the
study and reviewed its design."' According to news reports,
I12 Tang et al., supra note 1, at 659.
113 See Quanlin, supra note III ("Wang didn't apply for ethical evaluation of the
trial, instead fabricating the approval documents, according to CDC.").
114 Tang et al., supra note 1, at 659.
I15 See Quanlin, supra note Ill (citing a television report from China's state-run
television that aired on December 8, 2012).
116 See Tang et al., supra note 1, at 660 ("Fasting blood samples ... were attempted
from each subject on the mornings of days 1, 3, 7, 14, and 21 over the experimental
period.").
117 Quanlin, supra note 111.
118 See Tang et al., supra note 1, at 663 ("The authors' responsibilities were as
follows-GT: designed the study, implemented the field trial, supervised the data
analysis, and wrote the manuscript; YH: coordinated and supervised the study; SY:
conducted the study and collected the samples; YW: reviewed the study design and
supervised the study; GED: supervised and implemented the statistical analyses; MAG:
produced the intrinsically labeled rice and spinach; and RMR: designed the study and
served as the study physician. All authors reviewed the manuscript. None of the authors
had a conflict of interest related to this study.").
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however, those researchers variously denied involvement in the
study, knowledge of the published article, and knowledge that
genetically-modified food was used."'
VI. Analysis of Ethical Issues in the Golden Rice Case
A. The Process for Approval
With respect to the ethical review process, the published article
states that "[t]he study recruitment processes and protocol were
approved by the Institutional Review Board-Tufts Medical
Center in the United States and by the Ethics Review Committee
of Zhejiang Academy of Medical Sciences in China."'2 0 However,
no dates were specified.'2 '
We infer from the article that the ethical review process took
place in 2003.122 That was five years before the beginning of the
study and took place in a different province of China, which is a
serious concern.123 Moreover, there was no specific information
about the members of the ethics committees, except for the brief
sentence noted above.124  Who were the members of the ethics
committee? Was there a specialist in pediatrics and a
representative of the parents?
B. Risks and Benefits
The parents were frightened by the use of genetically modified
organisms and the possible risks.125 Moreover, as discussed above,
119 See Tom Bartlett, The Golden Rice Controversy, CHRONICLE OF HIGHER EDUC.
(Sept. 11, 2012), http://chronicle.com/blogs/percolator/the-golden-rice-
controversy/30836 ("One oddity is that last week government officials in China told
reporters that the study did not involve genetically modified rice and that it was not done
in association with American researchers-even though just a glance at the paper's
abstract indicates otherwise.").
120 Tang et al., supra note 1, at 659.
121 Id
122 Id.
123 Id. In addition to any factual or scientific changes that may have occurred in the
interim, there is also the significant possibility that the protocol for approval changed
during that time.
124 See supra note 120 and accompanying text.
125 See Quanlin, supra note IlI ("The development of genetically modified rice
enjoys strong government support in China, but the public remains sceptical [sic] about
its safety.").
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there was a misunderstanding about the amount of Golden Rice
eaten by the children who participated in the study. 2 6  The
published article described a study period, which lasted for three
weeks.127 Blood samples were collected from each subject on days
one, three, seven, fourteen, and twenty-one.128  Therefore, the
parents thought that their children ate Golden Rice during the
entire study period.129  The inconsistencies in Golden Rice
allocations were clear, as one researcher explained in a news
report.'30 "Either the researchers are lying about this now or they
lied about it in the paper. . . . [I]t's a serious offence either way,"
said Wang Zheng, of the Academy of Sciences' Institute of Policy
and Management in Beijing, referring to the differing estimations
as to exactly how much of the rice participants ingested."'
In addition, the study described on clinicaltrials.gov is a Phase
II study to determine the vitamin A value (equivalence) of dietary
provitamin A carotenes from spinach, Golden Rice, and pure P3
carotene in oil.'3 2 This means that there was no direct benefit for
the children involved in the research. Participants could have, at
best, benefitted indirectly from advances in the study of preventing
Vitamin A deficiency.
C. Informed Consent
As discussed above, the authors stated in their article that
"[b]oth parents and pupils consented to participate in the study."' 33
However, according to an investigative news story on China's
state television, parents did not know their children were eating
genetically-modified rice, and were not informed about any
potential risks of genetically-modified food.'34 Such consent was
126 See supra notes 102-103 and accompanying text (noting that it is unclear in
what amounts and at what times the children ingested Golden Rice).
127 See supra note 117 and accompanying text.
128 Tang et al., supra note 1, at 660.
129 See id. at 659 (the entire study was to last for thirty-five days, including a
fourteen day diet period).
130 See Qiu, supra note 93 (noting that it is unclear how much Golden Ric subjects
ingested).
'31 Id.
132 Vitamin A Equivalence, supra note 90.
133 Tang et al., supra note 1, at 659.
134 See Quanlin, supra note Ill ("[Nione of the children, their parents or school
2013 1001
N.C. J. INT'L L. & COM. REG.
clearly not informed, because all of the necessary information was
not provided.'35  Lack of informed consent is insufficient
protection for the subjects involved in research.136
The lack of informed consent was one of the grounds on which
Greenpeace and others raised ethical objections to this research.'
However, a well-known bioethicist in the United States, Art
Caplan, disagreed with some of those criticisms.'38 According to
Caplan:
[R]esearch involving children is often highly controversial.
Putting children at risk when there [is] no certainty of benefit in
the hope of gaining new knowledge is, at best, ethically dubious.
Research done on kids when the risk is great rightly sets all of
our moral teeth on edge. That is the charge Greenpeace is
screaming ethical bloody murder about. They say Chinese
children were given dangerous genetically engineered rice in a
study without any consent from the kids, parents or the approval
of the appropriate review bodies . . . . If these accusations were
true, this would be one of the worst research scandals of all time.
U.S.-funded research involving dangerous food made by big,
greedy U.S. companies tested on poor, innocent kids in rural
China with no consent-who could trust people willing to do
that? The only problem with Greenpeace's cry of scandal is that
it is nonsense. 39
In reaching his conclusion, Caplan relied on the published
article's claims about ethical review and consent, although he
teachers were aware that Golden Rice was involved, according to .. . CCTV, China's
state television channel.").
135 See id. (explaining that the parents were not properly informed and therefore
could not have provided fully informed consent when allowing their children to
participate in this study).
136 See supra Part III (discussing the worldwide ethical principles for human
subject research including the Declaration of Helsinki, CIOMS Guidelines, and the
Declaration by UNESCO).
137 See Art Caplan, Greenpeace Out to Sea on GM Rice Issue, Bioethicist Says,
NBCNEWS.COM (Jan. 11, 2013), http://vitals.nbcnews.com/_news/2012/09/14/13863010-
greenpeace-out-to-sea-on-gm-rice-issue-bioethicist-says?lite ("[Greenpeace] say[s]
Chinese children were given dangerous genetically engineered rice in a study without
any consent from the kids, parents or the approval of the appropriate review bodies.").
138 Id
139 Id
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recognizes that the parents might not have really understood.'40 In
other words, Caplan's conclusion is based on the assumption that
the researchers obtained-or at least tried to obtain-the informed
consent of the parents.141
But what if there really was no informed consent as a matter of
fact? Would that necessarily end the ethical analysis? Or are
there other ethical principles that would still need to be
considered?
The prevailing approach of modem bioethics is the theory of
principlism.'42 Under principlism, individuals have multiple
duties, and these duties might be in conflict.143 The moral duties
of principlism include beneficence (helping people), non-
maleficence (not harming people), honesty, justice (fairness), and
respect for individual autonomy (which is the basis for informed
consent).144 Depending on the specific circumstances, one duty
might take precedence over another.145 For example, we ordinarily
allow patients to refuse unwanted medical treatment under the
ethical principle of autonomy.146 Nevertheless, in some situations,
we might conclude that beneficence to a particular patient
outweighs that patient's autonomy. 147
Thus, we cannot reach a complete conclusion about the ethics
of the Golden Rice case merely by resolving the factual issue of
whether the parents and children consented to participate in the
research. An exclusive focus on informed consent would be
inconsistent with the prevailing bioethical approach of principlism,
which requires a balancing of conflicting moral duties.148 This
does not mean that the Golden Rice study was ethical. Rather, it
means that we need to consider whether another moral duty, such
as beneficence, might outweigh the duty of autonomy in the
140 Id
'41 Id
142 DEAN M. HARRIS, ETHICS IN HEALTH SERVICES AND POLICY: A GLOBAL
APPROACH 5-6 (2011).
143 Id
144 Id
145 Id
146 Id
147 Id
148 HARRIS, supra note 142, at 5-6.
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circumstances of this particular case.149
Even if informed consent was not truly obtained in the Golden
Rice study, would fulfilling the duty of beneficence by helping
people outweigh the lack of autonomy, which is the basis for
informed consent? On the facts of this case, neither the duty of
beneficence nor any other moral duty outweighed the duty of
autonomy or the imperative of informed consent for participation
in research. It is true that vitamin A deficiency is a serious
problem in public health.'so However, the objective of this
research was to demonstrate the equivalence of 13-carotene in oil
and in Golden Rice for the purpose of preventive strategies, and
not to administer a treatment for the deficiency.'"' Therefore, the
study could have been conducted on healthy adult volunteers who
would have been more likely to understand the principles and
necessity of informed consent. Even considering the other ethical
values that must be considered under principlism, the conclusion
remains the same-performing this type of research on human
subjects without consent is unethical.
Moreover, it is important to recognize that the consequences of
conducting research without consent extend far beyond the
individual subjects and their families. For example, allegations
that a U.S. pharmaceutical corporation failed to obtain informed
consent for a drug study in Nigeria subsequently caused the local
population to distrust doctors and researchers and, thereby,
hindered later efforts to control a polio outbreak.'52 Furthermore,
the use of a fake vaccination scheme by the U.S. Central
Intelligence Agency (CIA) during the hunt for Osama bin Laden
further interfered with efforts to control polio, and might have
149 Nor does it end the ethical discussion to say that the study apparently violated
U.S. and Chinese laws. In some situations, an ethical imperative, such as saving lives,
might require doing something contrary to law. This is not to suggest that a violation of
law would have been justified in this particular case. Rather, the point is that merely
demonstrating a violation of law would not terminate all ethical analysis.
150 See Tang et al., supra note 1, at 658 (citing reports by the World Health
Organization and UNICEF).
151 Id. at 662.
152 See Abdullahi v. Pfizer, 562 F.3d 163, 186-87 (2d Cir. 2009) (noting that
"failure to secure consent for human experimentation has the potential to generate
substantial anti-American animus and hostility"); see also HARRIS, supra note 142, at
116-17 (discussing the complex litigation resulting from Pfizer's alleged failure to obtain
informed consent for Nigerian children's participation in a clinical trial).
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contributed to the killing of anti-polio workers by Pakistani
citizens.153  As Lynn Goldman and Michael Klag have written,
"[w]hen the CIA enlisted a Pakistani doctor to run a fake
vaccination program as part of an effort to hunt down Osama bin
Laden, it stoked fears that vaccine workers are all potential
spies."l5 4 Obviously, those cases are distinguishable on the facts
from the Golden Rice study in China. However, those cases
highlight the severe consequences that can occur when
organizations and government agencies from Western countries
act in ways that generate distrust and suspicion among residents of
developing nations. For that reason, as well as for the other
reasons discussed above, the duty of beneficence did not outweigh
the duty of autonomy or the imperative of informed consent for
participation in research. Performing this type of research on
human subjects without consent is unethical.
VII. Recommendations for Reform: Lessons from the
"Golden Rice" Study
For Chinese lawmakers, many lessons can be learned from the
"Golden Rice" study. First, the study presents the question: in
what type of research should minors be allowed to participate?
Currently, Chinese law does not specifically restrict or proscribe
research on minors. Article 15, Section 3 of "Good Clinical
Practice of Pharmaceutical Clinical Trials," 55 promulgated by the
State Food and Drug Administration of China, requires that
research "involving children as subjects must get the informed
consent from their legal guardians. . . . If the children are able to
make [the] decision to participate [in] the research, their own
assent must be obtained too.""' Therefore, the only mechanism
provided to protect minors from becoming involved in
inappropriate clinical trials is the process of obtaining informed
153 Lynn R. Goldman & Michael J. Klag, CIA Deception Threatens Global Effort to
Eradicate Polio, BALTIMORE SUN (Jan. 7, 2013), http://articles.baltimoresun.com/2013-
01-07/news/bs-ed-polio-20130107_Ipolio-vaccine-fake-vaccination-program-global-
polio-eradication-initiative.
154 Id
155 Clinical Trials of Drug Quality Management Practices State Food and Drug
Administration Order No. 3, STATE FOOD & DRUG ADMINISTRATION,
http://www.sda.gov.cn/WSOI/CL0053/24473.html (last visited Apr. 18, 2013).
156 Id.
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consent from their guardians and assent from the minors
themselves. However, due to the imbalance of information
between the researchers and potential participants or their
guardians, and the lack of medical knowledge on the part of the
latter, informed consent is generally not sufficient to guarantee the
rights and interests of the minors.
Article 15 of the Additional Protocol to the Oviedo
Convention15 1 makes a distinction between two categories of
research based on the presence of a potential to produce real and
direct benefit to the potential minor participant.5  If there is no
direct possibility to benefit the participant, the research may be
conducted when, and only when
[t]he research has the aim of contributing, through significant
improvement in the scientific understanding of the individual's
condition, disease or disorder, to the ultimate attainment of
results capable of conferring benefit to the person concerned or
to other persons in the same age category or afflicted with the
same disease or disorder or having the same condition.' 59
Furthermore, the research can only entail a "minimal risk and
minimal burden for the individual concerned; any consideration of
additional potential benefits of the research shall not be used to
justify an increased level of risk or burden." 6 0
The method of risk/benefit evaluation which is required in the
United States by the Common Rule' 6 ' divides research with minor
participants into three categories: (1) research with only minimal
risk;162 (2) research with above minimal risk and direct benefit to
the participant;163 and (3) research with above minimal risk and
without direct benefit to the participant, "but likely to yield
generalized knowledge about the subject's disorder or
157 Council of Europe Bioethics Division, Additional Protocol to the Convention on
Human Rights and Biomedicine, Concerning Biomedical Research art. 15, opened for
signature Jan. 25, 2005, E.T.S. 195, (entered into force Sept. 1, 2007), available at
http://conventions.coe.int/Treaty/en/Freaties/Html/195.htm.
158 See id art. 15(l)-(2).
159 Id. art. 15(2)(i).
160 Id. art. 15(2)(ii).
161 See 45 C.F.R. §§ 46.401-09 (2013).
162 Id. § 46.404.
163 Id. § 46.405.
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condition." 64 Aside from informed consent by the participants'
guardians and assent by the participants themselves if possible, the
U.S. Common Rule requires the last two categories of research to
pass the risk/benefit evaluation before the research is authorized.'6 5
We recommend that Chinese law adopt a similar mechanism
of classification. Clinical trials could be classified into different
categories, such as therapeutic and non-therapeutic research,
invasive research, and observational research. Therapeutic
research could be allowed with the informed consent of the
guardians and assent of the minors. Similar rules could also be
applied for observational research and temporary invasive
research. In contrast, for long-term invasive research, the
justification of the purpose of research and the acceptance of
minimal risk should be guaranteed at the outset. Furthermore, the
research must meet three additional requirements. First, the aim of
the research must be to solve a health problem of the population in
the same age category as the potential participant. Second, it must
be true that the aim of the research could not be achieved by
research involving adults or an older group of minors. Finally,
there shall not be any risks above the level of minimal risk,
including not only physical and psychological risks but also legal,
social, and economic risks.166
In addition to the foregoing ethical concerns, the Golden Rice
study took place at the site of a primary school.167 This draws
attention to the legal and ethical requirements that can justify
enrolling participants through their schools. We think there should
be both substantive and procedural requirements to do that.
Specifically, researchers must prove that the trial has potential to
improve the health of the students in the school in which the trial
would be conducted. Researchers must consider the possibility of
whatever influence and inconvenience the trial would bring to the
life and education in that specific school, and whether the age,
family background, health condition, and ability of comprehension
of the students are suitable for the trial. The decision to conduct a
164 Id. § 46.406.
165 See id §§ 46.405-06.
166 Hongjie Man, Legal Regulation on the Clinical Trials Involving Minors-
Lessons Learnt from the "Golden Rice" Test, LEGAL SCIENCE 2012, 57.
167 See supra note 98 and accompanying text.
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clinical trial in a particular school should be made jointly by the
school authority, the students, and their parents.168
Secondly, how can the procedure for ethical reviews be
reformed to do a better job of protecting the participants in clinical
trials? There are two types of ethical review bodies on the globe:
Institutional Review Boardsl69 as seen in the United States, and
administrative bodies of ethical review as seen in many European
countries.'70  In 2007, China's Ministry of Public Health
promulgated the Regulation of Ethical Review for Biomedical
Research Involving Human Beings.' 7 ' Article 6 requires all of the
universities, hospitals, and other research institutions to establish
their own Institutional Review Boards. 7 2 Therefore, the current
Chinese law adopted the American mode, rather than the European
mode of review. However, this type of institutional ethics review
does not work well in the context of Chinese practice. Committee
members have dual roles as "watchdogs" for the interests of
participants and as subordinates of the institution. 17 This leads
them into an awkward position framed by a conflict of interest, in
which they sometimes have to ignore the risks and potential harms
to participants in order to promote the scientific and economic
interests of their institution, their colleagues, and themselves.174
168 See Man, supra 166, at 57-58.
169 An Institutional Review Board is "any board, committee, or other group
formally designated by an institution to review biomedical research involving humans as
subjects, to approve the initiation of and conduct periodic review of such research." 21
C.F.R. § 50.3(i) (2013).
170 See supra Part IV.B (noting that the European Medicines Agency Reflection
Paper provides that EU Member States should obtain approval from an independent
ethics committee or its actions will be considered "a serious violation of ethical
standards"). Therefore, there is a presumption that the ethics committees are
independent from conflicts of interest.
171 Regulation for Biomedical Research Involving Human Beings, MINISTRY OF
PUBLIC HEALTH OF THE PEOPLE'S REPUBLIC OF CHINA, http://www.moh.gov.cn/
mohkjjys/s3581/200804/18816.shtml (last visited Apr. 17, 2013).
172 See id. art. 6.
173 See Man, supra note 166, at 58-59 (noting that boards would be reorganized due
to this double duty).
174 Weaknesses in the system for protecting human subjects are not limited to
developing countries. In fact, significant weaknesses have been identified in the system
of Institutional Review Board review in the United States. For example, in 2009, the
U.S. Government Accountability Office (GAO) testified before a Congressional
subcommittee about the failure of Institutional Review Boards to provide adequate
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Therefore, we strongly urge that the ethical review system be
reorganized to follow the administrative mode, which would
promote the most valuable principles for ethical review-
independence and neutrality.'
In the Golden Rice study, the Institutional Review Board
which authorized the trial was in Zhejiang Province, which is
around 800 kilometers away from the trial site in Hunan
Province.176 The World Health Organization (WHO) urges ethical
review to include the consideration of the interests of the
community where the trial is conducted.177 However, no evidence
demonstrated that there was any involvement by a representative
of the community, nor any involvement by a representative of the
students or their families. Our recommendation is that, before
children may participate in a trial, the ethical review committee
should be legally required to be comprised of at least one member
with educational expertise, as well as at least one representative of
protection for research subjects. U.S. Gov'T ACCOUNTABILITY OFFICE, GAO-99-448T,
HUMAN SUBJECTS RESEARCH: UNDERCOVER TESTS SHOW THE INSTITUTIONAL REVIEW
BOARD SYSTEM IS VULNERABLE TO UNETHICAL MANIPULATION (2009), available at
http://www.gao.gov/new.items/d09448t.pdf. According to the GAO:
Our investigation shows that the [Institutional Review Board] system is
vulnerable to unethical manipulation, particularly by companies or individuals
who intend to abuse the system or to commit fraud, or who lack the aptitude or
qualifications to conduct and oversee clinical trials. This vulnerability elevates
the risk that experimental products are approved for human subjects testing with
little or no substantive due diligence.
Id at 4. The GAO report made some distinctions between the newer "independent"
Institutional Review Boards and the more traditional "academic institution" Institutional
Review Boards. Id. at 1-2. However, it is not clear whether the older "academic
institution" Institutional Review Boards performed more or less effectively than the
newer alternatives. See id. In fact, the GAO report recognized that criticisms of the
effectiveness of Institutional Review Boards had been raised for many years. Id at 2
n.2.
175 Man, supra note 166, at 58-59.
176 See Distance Between Zhejiang and Hunan Province, DISTANCE CALCULATOR,
http://distancecalculator.globefeed.com/china Distance Result.asp?fromplace=Zhejiang
%201921%20CIub%20Hotel%20Jiaxing%20(Zhejiang)&toplace=HUNAN%20BESTRI
DE%20HOTEL%20(Hunan%20Province)&fromlat-30.7581&tolat=28.2&fromlng=120.
7502&tolng-I 12.9666 (last visited Apr. 17, 2013).
177 WORLD HEALTH ORG., OPERATIONAL GUIDELINES FOR ETHICS COMMITTEES THAT
REVIEW BIOMEDICAL RESEARCH, § 6.2.6 (2000), available at http://www.who.int/
tdr/publications/documents/ethics.pdf (explaining that an ethics committee should take
"community considerations" into account when reviewing research proposals).
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the interests of local students and their parents.'
Moreover, the Golden Rice study exemplifies the importance
of having on-site ethical review and supervision. The Regulation
of Ethical Review for Biomedical Research Involving Human
Beings gives ethical review committees the authority to conduct
on-site supervision and inspection.17 9 However, there are few
detailed and operational provisions to accomplish those
functions. "s We recommend that a procedure for on-site
supervision be included in the law, as well as provisions assuring
an unobstructed channel between the participants and the ethical
review committee.' 8'
Lastly, ensuring and protecting the minors' informed consent
is a major concern. In the Golden Rice study, researchers acquired
consent forms signed by participants' parents for all participating
minors.182  This indicated to the researchers that the standard of
informed consent had been satisfied.'8 3  However, according to
international standards, there are still several problems with the
study.
First, the children's opinions were not considered.
International ethical guidelines, such as the Declaration of
Helsinki, suggest that the opinion of a potential minor participant
should be respected by the researcher.'8 4 In the Golden Rice
study, the students ranged from ages six to eight when the trial
178 See Man, supra note 166, at 59-60.
179 See Regulation for Biomedical Research Involving Human Beings, supra note
171.
Iso See id
181 See Man, supra note 166, at 60.
182 See Mara Hvistendahl & Martin Enserink, Chinese Researchers Punished for
Role in GM Rice Study, SCI. INSIDER (Dec. 12, 2012, 12:40 PM),
http://news.sciencemag.org/scienceinsider/2012/12/chinese-researchers-punished-
for.html (noting that consent forms were signed by the parents of participating children).
183 See id. Furthermore, "[djefenders of the trial, including the U.S. National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which partly funded
the research, have countered that the scientists conducting the research got all the
necessary legal and ethical permissions." Id.
184 See DECLARATION OF HELSINKI, supra note 3, art. 28 ("When a potential
research subject who is deemed incompetent is able to give assent to decisions about
participation in research, the physician must seek that assent in addition to the consent of
the legally authorized representative. The potential subject's dissent should be
respected."). Id.
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started, which suggests that they had a certain level of
understanding.' However, there is no evidence that researchers
attempted to obtain the students' opinions or consent. The
researchers and the administration of the primary school believed
that they had fulfilled their duty to inform by distributing an
informed consent document during two parent meetings.'8 6
However, there was no sincere effort to explain the nature and
purpose of the trial to either the parents or the children
themselves. 8 1
The process of providing information to the potential
participants was not conducted in a comprehensible manner. Due
to the complexity of modem biomedical research, it is necessarily
difficult for potential participants, who typically have no
biomedical knowledge, to understand the nature of the trial.' 8
Moreover, there is an inevitable imbalance of information between
the parties. 189 As a result, in most cases involving biomedical
research, the potential participants give their consent with no true
comprehension of the situation or with a misunderstanding of the
situation.'9 0 Therefore, researchers should have a responsibility to
inform participants in a manner which is intelligible to each and
185 See Qiu, supra note 93.
186 See WORLD HEALTH ORG., STANDARDS AND OPERATIONAL GUIDANCE FOR
ETHICS REVIEW OF HEALTH-RELATED RESEARCH WITH HUMAN PARTICIPANTS 16 (2011)
[hereinafter WHO STANDARDS], available at http://whqlibdoc.who.int/publications/
2011/9789241502948_eng.pdf ("[T]hat a participant or surrogate may be willing to
consent to research does not, in itself, mean that the research is ethically acceptable.").
187 See Hvistendahl & Enserink, supra note 182 (stating that the full contents of the
consent form were not explained to parents and, instead, parents were simply shown the
area of the form that they were required to sign).
188 See, e.g., Kenneth Kipnis, Vulnerability in Research Subjects: A Bioethical
Taxonomy, ETHICAL AND POLICY ISSUES IN RESEARCH INVOLVING HUMAN PARTICIPANTS,
Vol. 2, National Bioethics Advisory Committee, G-6 (2001) (discussing the concept of
cognitive vulnerability).
189 See id. at G-3 (highlighting the disconnect between lawyers' expectation of
clients "who could understand a 12-page consent form and act intelligently on the basis
of its contents" and the reality of adult clients who are largely unaware of the
implications of the research project).
190 See, e.g., Hvistendahl & Enserink, supra note 182 (noting that because U.S.
guidelines regulating consent forms require that "[t]he information that is given to the
subject or representative shall be in a language understandable to [them]," the
researchers specifically avoided using the term "genetically modified"). Id. para. 8.
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every potential participant.19 ' Every piece of information should
be delivered in language that is understandable to each potential
participant, both linguistically and scientifically.19 2 If children are
involved, the researcher must take care to deliver as much
comprehensible information as possible to the children, according
to their age and level of understanding.'
In this case, the participants were also subject to undue
influence by the school administration. The Golden Rice study
was conducted in a primary school where the school authority
played an important, albeit dishonorable, role in the study.19 4 They
mobilized and urged all of the students aged six through eight to
"have a nutritious lunch," when, in fact, they were directing
students to participate in the study.'95 We can imagine the strong
influencing power that the school and teachers had in
manipulating the free will of the students and parents involved.
Furthermore, the school enticed students with a free lunch, which
would normally cost 500 RMB'96 per semester, thereby providing
a biasing economic inducement to the potential participants. We
recommend that the law forbid schools from participating in any
form of mobilizing, organizing, or encouraging of students to
participate in such programs. Finally, schools should not be able
to host projects or recruit eligible students, if doing so introduces
conflicts of interest.19 7
VIII. Conclusion
The Golden Rice case sheds light upon certain issues that may
191 See London, supra note 3, at 1080 (reaffirming that "reliance on procedural
aspects of consent is wholly insufficient to guarantee ethical standards in research" and
encouraging researchers to adjust consent procedures according to the participants'
cultural views and understanding).
192 See WHO STANDARDS, supra note 186, at 16-17 (encouraging extensive
interaction between researcher and community to promote clear communication); see 45
C.F.R. § 46.116 (2012) ("The information that is given to the subject or the
representative shall be in language understandable to the subject or the representative.").
193 See Man, supra note 166, at 61-62.
194 See id. (discussing the primary school's role in Golden Rice experiment).
'95 Id.
196 Id. As of April 14, 2013, 500 RMB (Chinese Yuan Renminbi) was equivalent
to $80.76. See Currencies, REUTERS, http://uk.reuters.com/business/currencies (last
visited Apr. 17, 2013) (providing up-to-date currency converter and currency table).
197 See Man, supra note 166, at 62-63.
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arise when conducting research in emerging countries and, as a
practical matter, demonstrates certain ways in which researchers,
regulators, and review committees can develop mechanisms to
prevent similar problems in the future.
First, practical experience encourages us to be skeptical that
procedures which were designed to protect patients and research
subjects will be followed routinely, even if those procedures were
formally written and approved. Next, researchers and research
sponsors cannot evade responsibility by delegating tasks to local
staff without providing for appropriate supervision. Finally,
experience teaches us to be skeptical about the effectiveness of
Institutional Review Board approval, as there may be conflicts of
interest or a lack of independent judgment.
Lawmakers anywhere can learn from the experiences, both
good and bad, of others. Different parts of the world use different
modes of ethical review for research with human subjects.' 8 By
studying these modes, lawmakers can select those that work best
to meet the specific needs within the context of their countries.
198 See supra Part III (discussing the laws and guidelines for specific countries and
regions).
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